Finance entity
Jason Kelly is most often covered alongside Bloomberg, which appears in 1 of these 2 stories. The 9-day window averages about 1.6 stories each week. Each story carries 2 original sources on average, compared with 2.7 for the broader beat in this window.
Last mentioned: Feb 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Jason Kelly is most often covered alongside Bloomberg, which appears in 1 of these 2 stories. The 9-day window averages about 1.6 stories each week. Each story carries 2 original sources on average, compared with 2.7 for the broader beat in this window. At 5.5, the average consequence score sits below the same-window beat average of 6.1. The clearest coverage concentration is earnings: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Finance stories that mention Jason Kelly, published between February 19, 2026 and February 27, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 807 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jason Kelly. Shared-story counts are live from our verified record — not editorial picks.
Divestiture Completion
Projected timeline for the formal separation of non-core biosecurity assets.
Earnings Release
Ginkgo reports a $0.38 EPS beat and releases full-year 2025 financial results.
Strategic Pivot
Company announces the divestiture of its biosecurity business and focus on Autonomous Labs.
Pre-Earnings Analysis
Market analysts provide insights into Ginkgo's upcoming results amid high expectations for cost-cutting updates.
Ginkgo Bioworks (NYSE: DNA) outperformed analyst expectations by $0.38 EPS in its latest quarterly report, signaling a potential shift in the company's financial trajectory. The results suggest that the synthetic biology leader's cost-cutting measures and platform scaling are beginning to deliver tangible bottom-line improvements.
HGGC, the private equity firm co-founded by NFL legend Steve Young and Rich Lawson, has successfully closed its fifth flagship fund at $3.2 billion. The oversubscribed fundraise highlights a rare success in a challenging capital-raising environment, drawing commitments from a diverse global base of institutional investors.
Jason Kelly is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
